All In Biotech

Drug Trial Radar · NCT06029270

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jul 15, 2024

Primary completion

Apr 30, 2029

Study completion Apr 30, 2029

Sponsor

Sponsor type
NIH
First posted
Sep 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.

Conditions

  • Metastatic Nasopharyngeal Carcinoma
  • Recurrent Nasopharyngeal Carcinoma
  • Stage IV Nasopharyngeal Carcinoma AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone ScanProcedure

    Undergo bone scan

  • CarboplatinDrug

    Given IV

  • CisplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • GemcitabineDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • RelatlimabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years

Locations

96 sites in 5 countries. Site status is shown where the registry gives one.

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Recruiting

  • Keck Medicine of USC Koreatown

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Modesto

    Modesto, California · Recruiting

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

  • Kaiser Permanente San Leandro

    San Leandro, California · Recruiting

  • Kaiser San Rafael-Gallinas

    San Rafael, California · Recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California · Recruiting

  • Kaiser Permanente-South San Francisco

    South San Francisco, California · Recruiting

  • Kaiser Permanente-Vallejo

    Vallejo, California · Recruiting

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Kaiser Permanente Moanalua Medical Center

    Honolulu, Hawaii · Recruiting

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho · Suspended

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho · Suspended

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Suspended

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Illinois

    Chicago, Illinois · Active not recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois · Recruiting

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.